Your browser doesn't support javascript.
loading
Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors.
Hsu, Hui-Te; Yu, Chu-Chun; Lee, Yun-Hsiang; Chan, Jui-Chun; Chu, Chia-Yu.
Afiliación
  • Hsu HT; Department of Dermatology, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  • Yu CC; School of Nursing, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Lee YH; Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
  • Chan JC; School of Nursing, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Chu CY; Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
Support Care Cancer ; 30(11): 9211-9219, 2022 Nov.
Article en En | MEDLINE | ID: mdl-36056941
PURPOSE: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are frequently associated with dermatologic adverse events (dAEs), having great impacts on patients' health-related quality of life (HRQoL) and treatment adherence. We aimed to examine the association between various dAEs and HRQoL in patients treated with EGFR-TKI therapy. METHODS: This was a cross-sectional study including 132 non-small-cell lung cancer (NSCLC) patients treated with gefitinib, erlotinib, afatinib, or osimertinib in Taiwan. The severity level of dAEs was graded by NCI-CTCAE v4.03 and PRO-CTCAE ITEMS v1.0. All participants answered the Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitors (FACT-EGFRI-18) HRQoL questionnaire. RESULTS: The clinician-reported severity of pruritus, photosensitivity, alopecia, and Karnofsky performance status was associated with HRQoL (ß = - 6.773, p = 0.046; ß = - 5.250, p = 0.032; ß = - 8.121, p = 0.001; ß = 0.327, p = 0.002; respectively). The clinician-reported severity of all dAEs except paronychia had negative correlations with HRQoL. The symptom gradings of CTCAE and PRO-CTCAE had positive correlation. CONCLUSIONS: The severity of pruritus, photosensitivity, and alopecia was associated with HRQoL of patients receiving EGFR-TKI therapy. Using patient-reported outcome measurements helps clinicians to capture the actual impact of symptoms on physical, social-emotional, and functional well-being.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2022 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2022 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Alemania